A Study of LY3451838 in Participants With Migraine

Migraine Clinical Trial

Official title:

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04498910
• Other study ID #: 17124
• Secondary ID: J1H-MC-LAJB
• Status: Completed
• Phase: Phase 2
• Start date: November 16, 2020
• Est. completion date: November 9, 2022

Study information

• Verified date: November 2023
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: November 9, 2022
• Est. primary completion date: November 9, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Must have a diagnosis of migraine with a history of migraine headaches of at least 1 year prior, and migraine onset prior to age 50.

• Have completed at least 80% of required daily diary entries during the start of the study.

• Have documentation of previous failure of 2 to 4 standard-of-care migraine preventive medication categories in the past 10 years.

• Women of child-bearing potential must test negative for pregnancy as indicated by a negative serum pregnancy test and negative urine pregnancy test.

• Women of child-bearing potential who are abstinent or in a same sex relationship must agree to either remain abstinent or to avoid sexual relationships with males.

• Women of child-bearing potential who are not abstinent, must agree to use one highly effective method of contraception, or a combination of two effective methods of contraception during the study, as well as 5 months following.

• Women not of childbearing potential may participate and include those who are: A. Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation) or congenital anomaly; or B. Post-menopausal - defined as either:

• i. a woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, and a follicle-stimulating hormone greater than (>) 40 multi-international units per milliliter (mIU/mL); or

• ii. a woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea; or

• iii. a woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy

Exclusion Criteria:

• Are currently enrolled in any other clinical study or any other type of medical research judged not to be compatible with this study.

• Have participated, within the last 30 days or 5-half-lives (whichever is longer), in a clinical study involving any investigational product. If the half-life of the investigational product is unknown, 6 months should have passed prior.

• Known hypersensitivity or intolerance to monoclonal antibodies or other therapeutic proteins, or to common antihistamines, epinephrine, methyl prednisone or other systemic corticosteroids.

• Are currently receiving medication or other treatment for prevention of migraine headaches. Participants must have discontinued such medications or treatments at least 2 weeks prior. Botulinum toxin A or B that has been administered in the head or neck area use must be discontinued at least 3 months prior. Nerve blocks or device use (such as transcranial magnetic stimulation or electrical nerve stimulation) in the head or neck area for migraine treatment must be discontinued at least 30 days prior. Anti-calcitonin gene-related peptide (CGRP) antibodies must be discontinued at least 5 half-lives prior.

• Have previously failed more than 4 migraine preventive medication categories in the past 10 years due to inadequate efficacy (that is, maximum tolerated dose for at least 2 months) and/or safety / tolerability reasons.

• History of cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, retinal migraine, typical aura without headache, complications of migraine and migraine with brainstem aura (basilar-type migraine).

• In the 3 months prior, have other types of headache besides migraine, tension type headache, or medication overuse headache (MOH). (In other words, participants can have migraine, tension type headache, or MOH in the 3 months prior, but they cannot have other types of headache in that time).

• History of head or neck injury within last 6 months.

• History of traumatic cervical or head injury associated with significant change in the quality or frequency of headaches.

• Have reading of electrocardiogram (ECG) showing abnormalities considered incompatible with the study.

• Any liver tests outside the normal range.

• Evidence of significant active or unstable psychiatric disease.

• Women who are pregnant or nursing.

• Participants who have used opioids or barbiturate-containing analgesic >4 days per month for the treatment of pain in each of the past 3 months.

• History of drug or alcohol abuse/dependence within 1 year.

• Have a positive urine drug screen for illicit drugs.

• Are unwilling or unable to comply with the use of data collection devices.

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Drug:
• LY3451838
Administered IV
• Placebo
Administered IV

Locations

Country	Name	City	State
United States	Health Research of Hampton Roads Inc	Newport News	Virginia
United States	Renstar Medical Research	Ocala	Florida
United States	Emerald Coast Center for Neurological Disorders	Pensacola	Florida
United States	21st Century Neurology, a division of Xenoscience	Phoenix	Arizona
United States	StudyMetrix Research	Saint Peters	Missouri
United States	Clinvest Research LLC	Springfield	Missouri
United States	New England Institute for Clinical Research	Stamford	Connecticut
United States	University of South Florida	Tampa	Florida
United States	Bio Behavioral Health	Toms River	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in the Number of Monthly Migraine Headache Days During 1-Month	Migraine Headache Day is a calendar day on which a migraine or probable migraine headache occurs. Per International Headache Society [IHS] International Classification of Headache Disorders version 3 [ICHD-3], migraine is defined as a headache, with or without aura, of >=30 minutes duration with both of the following required features (A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity (B) During headache at least 1 of the following: Nausea and/or vomiting; Photophobia and phonophobia. Least square mean was assessed using Bayesian Mixed Model Analysis with baseline number of monthly migraine headache days as a covariate.	Baseline, Month 1
Secondary	Change From Baseline in the Number of Monthly Headache Days During 3-Month	Migraine Headache Day is a calendar day on which a migraine or probable migraine headache occurs. Per International Headache Society [IHS] International Classification of Headache Disorders version 3 [ICHD-3], migraine is defined as a headache, with or without aura, of >=30 minutes duration with both of the following required features (A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity (B) During headache at least 1 of the following: Nausea and/or vomiting; Photophobia and phonophobia. Least square mean was assessed using Bayesian Mixed Model Analysis with baseline number of monthly migraine headache days as a covariate.	Baseline, Month 3
Secondary	Percentage of Participants With =50% Reduction From Baseline in Monthly Migraine Headache Days	Percentage of Participants with =50% Reduction from Baseline in Monthly Migraine Headache Days are reported.	Month 1
Secondary	Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs)	Number of Participants with at least one TEAEs are reported. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.	Baseline up to 5 Months
Secondary	Number of Participants With at Least One Serious Adverse Events (SAEs)	Number of Participants with at least one SAEs are reported. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.	Baseline up to 5 Months
Secondary	Pharmacokinetics (PK): Area Under the Serum Concentration-time Curve From Time 0 to the Last Measurable Serum Concentration (AUC 0-t) of LY3451838	PK: AUC(0-t) of LY3451838	Pre-infusion, end of infusion, 3hours(h), 365h, 730h, 1095h, 1460h, 1825h, 2190h, 2920h, 3650h post-infusion
Secondary	PK: Maximum Observed Serum Concentration (Cmax) of LY3451838	PK: Cmax of LY3451838	Pre-infusion, end of infusion, 3hours(h), 365h, 730h, 1095h, 1460h, 1825h, 2190h, 2920h, 3650h post-infusion

External Links

•   A Study of LY3451838 in Participants With Migraine